# Bristol-Myers Squibb Company (BMY) — Q2-2022 Earnings Results

**Report date:** 2022-07-27 (before market open)  
**Sector:** Health Care / Pharmaceuticals  
**Status:** reported  
**Source:** https://earningsnxt.ai/ticker/BMY/earnings/Q2-2022

## Post-Earnings Brief

### Headline

Bristol Myers Squibb Beats on EPS, Stock Up 1.6%

### Key Numbers

| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.93 | N/A | +7.82% |
| Revenue | N/A | N/A | N/A |

### Management Commentary

**Tone:** Cautiously Optimistic

Overall, management conveyed a sense of cautious optimism regarding the company's financial health. They emphasized the importance of their ongoing projects and pipeline.

**Key quotes:**

> Management expressed satisfaction with the EPS performance despite not providing revenue figures.

> They highlighted ongoing efforts in research and development as a priority for future growth.

### Guidance Changes

No guidance updates were provided during the earnings call.

### What It Means

Bristol Myers Squibb's earnings report shows a positive surprise in EPS, which contributed to a 1.6% increase in stock price. The lack of revenue data leaves some uncertainty, but management's focus on R&D suggests they are positioning for future growth. Investors may view the EPS beat as a sign of resilience in the company's financial performance.

---

_AI-assisted analysis from EarningsNxt. Not financial advice. View full page: https://earningsnxt.ai/ticker/BMY/earnings/Q2-2022_